HIT! High Impact Clinical Trials 3

29 Mar 2026 2:10 p.m. 3:10 p.m.

Main Hall

- In IgA Nephropathy and Others

Sydney Tang Chair Hong Kong, China

Time	Session

2:10 p.m. 2:22 p.m.	Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist) HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
2:22 p.m. 2:34 p.m.	Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial XiaobingYang Speaker yxb7829@163.comChina
2:34 p.m. 2:46 p.m.	Efficacy and Safety of Iptacopan in Patients With Iga Nephropathy (IgAN): Final 24-month Results From the Phase Iii Applause-IgAN Study VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia
2:46 p.m. 2:58 p.m.	ASPIRE Trial: Aspirin Use in Dialysis Patients in China XueqingYu Speaker yuxueqing@gdph.org.cnChina
2:58 p.m. 3:10 p.m.	Q&A